Multigene Expression Assays for Predicting Recurrence in Colon Cancer

Policy # 00257
Original Effective Date: 04/13/2010
Current Effective Date: 03/21/2018

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers gene expression assays for determining the prognosis of stage II or stage III colon cancer following surgery to be investigational.*

Background/Overview
Of patients with stage II colon cancer, 75% to 80% are cured by surgery alone, and the absolute benefit of chemotherapy for the overall patient population is small. Patients most likely to benefit from chemotherapy are difficult to identify by standard clinical and pathologic risk factors. Genomic tests are intended to facilitate identifying stage II patients most likely to experience recurrence after surgery and most likely to benefit from additional treatment.

Colorectal cancer (CRC) is classified as stage II (also called Dukes B) when it has spread outside the colon and/or rectum to nearby tissue but is not detectable in lymph nodes (stage III disease, also called Dukes C) and has not metastasized to distant sites (stage IV disease). Primary treatment is surgical resection of primary cancer and colonic anastomosis. After surgery, the prognosis is good, with survival rates of 75% to 80% at 5 years. A 2008 meta-analysis of 50 studies of adjuvant therapy vs surgery alone in stage II patients found a statistically significant, though small, absolute benefit of chemotherapy for disease-free survival but not for overall survival. Therefore, adjuvant chemotherapy with 5-fluorouracil or capecitabine is recommended only for resected patients with high-risk stage II disease (i.e., those with poor prognostic features).

However, the clinical and pathologic features used to identify high-risk disease are not well-established, and patients for whom benefits of adjuvant chemotherapy would most likely outweigh harms cannot be identified with certainty. The current diagnostic system relies on a variety of factors, including tumor substage IIB (T4A tumors that invade the muscularis propria and extend into pericolorectal tissues) or IIC (T4B tumors that invade or are adherent to other organs or structures), obstruction or bowel perforation at initial diagnosis, an inadequately low number of sampled lymph nodes at surgery (≤12), histologic features of aggressiveness, a high preoperative carcinoembryonic antigen level, and indeterminate or positive resection margins.

Of interest, a 2010 review has noted that microsatellite instability and mismatch repair deficiency in colon cancer may represent confounding factors to be considered in treatment. These factors may identify a
minority (15%-20%) of the population with improved disease-free survival who may derive no benefit or may exhibit deleterious effects from adjuvant 5-fluorouracil plus leucovorin–based treatments. Patient microsatellite instability and mismatch repair status may be critically important in how to study, interpret, and use a particular gene expression profiling (GEP) test.

**FDA or Other Governmental Regulatory Approval**

U.S. Food and Drug Administration (FDA)

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. Multigene expression assay testing for predicting recurrent colon cancer is available under the auspices of Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the U.S. FDA has chosen not to require any regulatory review of this test.

GEP tests for colon cancer currently commercially available include:

- **ColoPrint®‡18-Gene Colon Cancer Recurrence Assay (Agendia)**
- **GeneFx™ Colon** (Helomics Therapeutics; also known as ColDx, Almac Diagnostics)
- **OncoDefender-CRC™‡** (Everist Genomics)
- **Oncotype DX®‡ Colon Recurrence Score** (Genomic Health).

**Centers for Medicare and Medicaid Services (CMS)**

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

**Rationale/Source**

Validation of genotyping to improve treatment outcomes is a multistep process. In general, important steps in the validation process address the following: analytic validity, which measures technical performance (i.e., whether the test accurately and reproducibly detects gene markers of interest); clinical validity, which measures the strength of associations between selected genetic markers and clinical status; and clinical utility, which determines whether the use of genotyping for specific genetic markers to guide treatment decisions improves patient outcomes (e.g., survival or adverse event rates) compared with standard treatment without genotyping.

**STAGE II OR III COLON CANCER**

**Clinical Context and Test Purpose**

The purpose of prognostic testing of diagnosed disease is to predict natural disease course (e.g., aggressiveness, the risk of recurrence, death). This type of testing uses gene expression of affected tissue to predict the course of the disease. The criteria under which prognostic testing may be considered clinically useful are as follows:
• An association of the marker with the natural history of the disease has been established; and
• Clinical utility of identifying the variant has been established, eg, by demonstrating that testing will lead to changes in clinical management of the condition or changes in surveillance.

The question addressed in this evidence review is: Does prognostic testing using the GEP tests described below in individuals diagnosed with stage II or stage III colon cancer improve the net health outcome?

The specific clinical context of each test is described briefly in the following section. The following PICOTS were used to select literature to inform this review.

**Patients**
The relevant population of interest is patients who have undergone surgery for stage II or stage III colon cancer and are being evaluated for adjuvant chemotherapy.

**Interventions**
The interventions of interest are GEP with the ColoPrint 18-Gene Colon Cancer Recurrence Assay, GeneFx Colon (ColDx), OncoDefender-CRC, and Oncotype DX Colon Recurrence Score.

**Comparator**
The comparator of interest is standard care without prognostic testing. The current standard of care is not to provide adjuvant chemotherapy to patients with stage II colon cancer and to administer adjuvant chemotherapy routinely to patients with stage III colon cancer.

**Outcomes**
The outcomes of interest are recurrence risk, recurrence-free survival, and overall survival at follow-up in patients classified as low risk, medium risk, or high risk by GEP.

**Time**
The time of interest is 5 to 10 years after surgical resection to assess colon cancer recurrence.

**Setting**
These tests are offered commercially through various manufacturers and would be performed on tumor tissue after surgical resection.

**Analytic Validity**
Many GEP assays have been developed and reported as prognostic markers in stage II colon cancer since 2004. Four are currently offered commercially in the United States (ColoPrint 18-Gene Colon Cancer Recurrence Assay, GeneFx Colon, OncoDefender-CRC, Oncotype DX Colon Recurrence Score). Information on specimen type, sample handling, and technique used for GEP has been reported for many of these assays.
Multigene Expression Assays for Predicting Recurrence in Colon Cancer

Policy # 00257
Original Effective Date: 04/13/2010
Current Effective Date: 03/21/2018

Clinical Validity

ColoPrint 18-Gene Colon Cancer Recurrence Assay
Salazar et al (2011) described the development of an 18-gene expression test called the ColoPrint 18-Gene Colon Cancer Recurrence Assay. A total of 188 samples were prospectively collected from patients with CRC. Ribonucleic acid (RNA) was isolated from fresh tissue frozen in liquid nitrogen, labeled and hybridized to customized whole-genome oligonucleotide high-density microarrays. A cross-validation procedure was performed on 33,834 gene probes that showed variation across the training samples. They were scored for their association with 5-year distant metastasis-free survival. From this pool of genes, an optimal set of 18 nonredundant probes was identified and used to construct classification scores for the test. Results were dichotomized into a 2-category, low- and high-risk, scoring system.

A small independent validation study by Salazar et al (2011) used a patient cohort of 206 patients. However, only 56% represented stage II tumors. Risk classification and survival are shown in Table 1 for the patients with stage II disease in this study.

Maak et al (2013) conducted a subsequent validation study in fresh-frozen tumor samples from patients who had undergone curative resection for stage II colon cancer. Mismatch repair status, clinical parameters, and follow-up data (median, 8.4 years) were collected. Five-year distant metastasis-free survival for patients classified as low risk and high risk is shown in Table 1. Information about net reclassification and clinical utility was not provided.

Table 1. RFS in Patients With Stage II Colon Cancer Assessed With ColoPrint

<table>
<thead>
<tr>
<th>Author (Year)</th>
<th>Follow-Up, y</th>
<th>N</th>
<th>Low Risk, %</th>
<th>Mean RFS for Low Risk, %</th>
<th>High Risk, %</th>
<th>Mean RFS for High Risk, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salazar et al (2011)</td>
<td>5</td>
<td>115</td>
<td>63.2</td>
<td>90.9</td>
<td>36.8</td>
<td>73.9</td>
</tr>
<tr>
<td>Maak et al (2013)</td>
<td>8.4</td>
<td>135</td>
<td>95</td>
<td></td>
<td>80</td>
<td></td>
</tr>
</tbody>
</table>

RFS: recurrence-free survival.

In 2015, Kopetz et al reported on a pooled analysis of 416 patients with stage II colon cancer from independent cohorts in the United States, Spain, Italy, Austria, and Germany. Investigators compared the prognostic ability of ColoPrint with National Comprehensive Cancer Network (NCCN) risk prediction based on clinicopathologic factors (T4; high-grade tumor; lymphovascular or perineural invasion; perforation or obstruction; <12 lymph nodes examined; positive margins). Recurrence risk at a mean 81 months (range, 56 to 178) is shown in Table 2. Statistical comparison of the risk models (e.g., using a likelihood ratio test and/or receiver operating characteristic curves) and comparison of classifications by survival outcomes (i.e., reclassification analysis) were not provided. Further, a 5-year recurrence risk as high as 14% in patients classified as low risk by ColoPrint may be too high for some patients to consider forgoing chemotherapy.

Table 2. ColoPrint and NCCN Risk Prediction and RR in Patients With Stage II Colon Cancer

<table>
<thead>
<tr>
<th>Author (Year)</th>
<th>Risk Predict</th>
<th>Low Risk, %</th>
<th>Mean RR for Low Risk R</th>
<th>High Risk, %</th>
<th>Mean RR for High Risk R</th>
</tr>
</thead>
</table>

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Multigene Expression Assays for Predicting Recurrence in Colon Cancer

Policy # 00257
Original Effective Date: 04/13/2010
Current Effective Date: 03/21/2018

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.

Page 5 of 13

Table 3. RFS in Patients With Stage II Colon Cancer Assessed With GeneFx

<table>
<thead>
<tr>
<th>Author (Year)</th>
<th>Follow-Up, y</th>
<th>N</th>
<th>Low Risk, n (%)</th>
<th>Mean RFS for Low Risk (95% CI)</th>
<th>High Risk, n (%)</th>
<th>Mean RFS for High Risk (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Niedzwecki et al (2016)</td>
<td>5</td>
<td>393</td>
<td>177 (45)</td>
<td>91 (89 to 93)</td>
<td>216 (55)</td>
<td>82 (79 to 85)</td>
</tr>
</tbody>
</table>

CI: confidence interval; RFS: recurrence-free survival.

OncoDefender-CRC

Lenehan et al (2012) reported on the development of a 5-gene test, OncoDefender. A total of 417 cancer-associated genes were preselected for study in archived FFPE primary adenocarcinoma tissues of 74...
patients with CRC (15 with stage I disease, 59 with stage II disease; 60 with a colon cancer, 14 with rectal cancer). Patients were divided into a training set and a test set. Cross-validation was performed to estimate the ability of the classifier to generalize to unseen samples. The most important feature of gene fitness was the area under the receiver operating characteristic curve for each gene.

In addition, Lenehan performed external validation on 251 patients with stage I and II colon cancer obtained from an international study set. Patient dropout from the set of archived samples used was substantial; only 264 (55%) of 484 patients with lymph node–negative CRC satisfied the initial clinicopathologic screening. This included a mix of patients with both rectal and colon cancer (stages I and II). The test appeared to distinguish patients at high vs low risk of recurrence (HR=1.63; p=0.031). Sensitivity and specificity of OncoDefender were compared with NCCN guidelines and showed similar sensitivity (69% vs 73%), with improved specificity (48% vs 26%). However, the isolated performance of the test in patients with stage II colon cancer was not reported, and several NCCN high-risk findings (bowel obstruction or perforation and lymphovascular invasion) demonstrated higher HRs than observed with the molecular signature. The study alluded to but did not directly address clinical utility.

**Oncotype DX Colon Recurrence Score**

O'Connell et al (2010) described the development of a 12-gene expression test, Oncotype DX Colon Recurrence Score. A total of 761 candidate genes of possible prognostic value for recurrence or of possible predictive value for treatment were examined by correlating the genes in tumor samples with clinical outcomes in 1851 patients who had surgery with or without adjuvant 5-fluorouracil-based chemotherapy. Gene expression was quantified from microdissected, FFPE primary colon cancer tissue. Of 761 candidate genes, multivariate analysis (including disease severity, stage, and nodal involvement) reduced the gene set to a 7-gene prognostic signature and a separate 6-gene predictive signature. Five reference genes also are included in the assay.

There have been several validation studies, with data summarized in Tables 4 and 5. External validation of the algorithm was first reported by Gray et al in 2011, who used FFPE primary tumor samples from patients with stage II colon cancer who had participated in the Quick and Simple and Reliable study. The relation between the 7-gene recurrence score and risk of recurrence was statistically significant, with 3-year risk of recurrence for predefined low-, intermediate-, and high-risk groups as shown in Table 4. In the surgery-alone group, the HR for recurrence in the high-risk group compared with the low-risk group was 1.47 (95% confidence interval [CI], 1.01 to 2.14, p=0.046).

### Table 4. Oncotype DX Validation Study Characteristics

<table>
<thead>
<tr>
<th>Author (Year)</th>
<th>Study</th>
<th>Study Design</th>
<th>N</th>
<th>Colon Cancer, n</th>
<th>Randomized Comparators</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gray et al (2011)</td>
<td>QUASAR</td>
<td>RCT</td>
<td>3239</td>
<td>1436</td>
<td>• Adjuvant chemotherapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>580</td>
<td>• Surgery alone</td>
</tr>
<tr>
<td>Venook et al (2013)</td>
<td>CALGB 9581</td>
<td>RCT</td>
<td>1713</td>
<td>690</td>
<td>• Edrecolomab</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1023</td>
<td>• Observation</td>
</tr>
</tbody>
</table>

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
In 2013, Venook et al. reported on a validation study using tumor tissue from patients with stage II colon cancer who had participated in the randomized CALGB 9581 trial. The investigators selected samples stratified by treatment group from those who had tumor tissue available (40% of the original patient sample). They used recurrence score cut points of 29 and 39 to determine low-, intermediate-, and high-risk groups (see Table 4); these values differ from the cut points of 30 and 41 validated in the Quick and Simple and Reliable study (previously described). In multivariate analysis, every 25-unit change in recurrence score was associated with recurrence independent of tumor stage, tumor grade, mismatch repair status, presence or absence of lymphovascular invasion, and the number of nodes assessed.

Yothers et al. (2013) conducted a validation study using tumor tissue from 264 patients with stage II colon cancer who had participated in the National Surgical Adjuvant Breast and Bowel Project (NSABP) C-07 trial. NSABP C-07 randomized 2409 patients with stage II (28%) or stage III (72%) colon cancer to adjuvant chemotherapy with 5-fluorouracil plus leucovorin or oxaliplatin plus 5-fluorouracil plus leucovorin. For the randomly selected sample of 50% of patients with stage II colon cancer, estimated 5-year recurrence risks (adjusted for treatment) are shown in Table 5. Five-year recurrence risk, estimated by Kaplan-Meier analysis, was reduced in high-risk patients who received oxaliplatin (9%; 95% CI, 3% to 25%) compared with those who did not (23%; 95% CI, 12% to 42%), but this difference was not observed in low- or intermediate-risk patients. However, CIs for these estimates were wide due to small numbers of patients and events in each risk group. For all stage III patients in any risk class, adjusted 5-year recurrence risk estimates exceeded 15%.

Table 5. Recurrence Rates With 3-Level Oncotype DX Colon Cancer Recurrence Risk Score

<table>
<thead>
<tr>
<th>Author (Year)</th>
<th>Study</th>
<th>Mean Recurrence Rate (95% CI), %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gray et al (2011)</td>
<td>QUASAR</td>
<td>3 (12.10 to 15)</td>
</tr>
<tr>
<td>Venook et al (2013)</td>
<td>CALGB 9581</td>
<td>5</td>
</tr>
<tr>
<td>Yothers et al (2013)</td>
<td>NASBP C-07</td>
<td>5</td>
</tr>
<tr>
<td>Reimers et al (2014)</td>
<td>TME stage II cohort (rectal)</td>
<td>5</td>
</tr>
</tbody>
</table>
Multigene Expression Assays for Predicting Recurrence in Colon Cancer

Policy # 00257
Original Effective Date: 04/13/2010
Current Effective Date: 03/21/2018

CALGB 9581: Cancer and Leukemia Group B 9581 trial; CI: confidence interval; NASBP C-07: National Surgical Adjuvant Breast and Bowel Project; QUASAR: Quick and Simple and Reliable; TME: Dutch total mesenteric excision trial.

Reimers et al (2014) conducted a retrospective study using prospectively collected tumor specimens from the Dutch total mesenteric excision trial in patients with resectable rectal cancer. Reimers used available tumor tissue from 569 stage II and III patients randomized to surgery alone. Among 130 patients with stage II rectal cancer, Oncotype DX classified 63 (49%) patients as low-risk, 37 (28%) patients as intermediate-risk, and 30 (23%) patients as high-risk. Five-year Kaplan-Meier recurrence risk estimates in the low-, intermediate-, and high-risk groups are shown in Table 5. Oncotype DX risk classification and estimated recurrence risks for patients with stage III rectal cancer were not reported.

The SUNRISE study (Yamanaka et al, 2016) evaluated tissue samples from consecutive patients with stage II and stage III colon cancer who had been treated with surgery alone. This was the standard of care at hospitals in Japan during the study period 2000 to 2005. From the total cohort of 1487 patients, samples were randomly selected from patients who had or did not have a recurrence, in a 1:2 ratio. The final number of patients studied was 597; 202 patients had disease recurrence, and 395 had no recurrence. As shown in Table 5, the risk of recurrence in patients with stage III colon cancer with a low-risk score was similar to patients with stage II disease and a high-risk score and exceeded 15%. When adjusted for disease stage, a 25-unit increase in the recurrence score had an HR of 2.05 (95% CI, 1.47 to 2.86; p<0.001).

Section Summary: Clinical Validity
Several validation studies of GEP for colon cancer have reported that testing provides prognostic information on the risk of recurrence. Some studies have reported that GEP testing offers prognostic information in a multivariate analysis. Other data have suggested that GEP testing may provide modest incremental prognostic information over the standard prognostic workup, including the NCCN risk prediction model. Patients with a low recurrence score have a lower risk of recurrence and patients with a high-risk score have a higher risk of recurrence. However, the increase in recurrence risk for a high-risk score is small, and it is uncertain whether the degree of increase is sufficient to intensify management.

Clinical Utility
Clinical utility is defined as how the results of the prognostic test will be used to change management of the patient and whether these changes in management lead to clinically important improvements in health outcomes.

A technical brief, published by the Agency for Healthcare Research and Quality in 2012, reviewed the clinical evidence for GEP in predicting outcomes, including the benefit from adjuvant chemotherapy, in patients with stage II colon cancer. The 4 commercially available assays reviewed herein were included in the brief. No prospective studies were identified that assessed change in net health outcome with use of a GEP assay, and no studies were identified that used a net reclassification analysis and subsequently evaluated the impact of the reclassification on net health outcome. Additionally, evidence was limited on the reproducibility of test findings, indications for GEP testing in stage II patients, and whether results of GEP
assays can stratify patients into groups with clinically meaningful differences in recurrence risk. No studies have been identified in subsequent literature updates that evaluated the impact of GEP testing on recurrence in patients with stage II or III colon cancer.

Direct evidence for the clinical utility of GEP testing to improve health outcomes is lacking. Therefore, a chain of evidence may be developed, which addresses 2 key questions.

1. Does the use of GEP testing of colon cancer risk in individuals with stage II or stage III colon cancer lead to a change in management regarding use of adjuvant chemotherapy?
2. Do those management changes improve health outcomes?

Several studies have documented changes in management following GEP testing for colon cancer. For example, in 2016, Brenner et al published a retrospective study of the association between Oncotype DX recurrence score and management decisions. The study included 269 patients from a health plan who had stage II colon cancer, mismatch repair proficient status, and Oncotype DX recurrence scores. The primary outcome measure was changes in management that occurred following Oncotype DX testing. Patients were classified as having either an increase in the intensity of surveillance/treatment, a decrease in the intensity of surveillance/treatment, or no change. A change in management following testing was found for 102 (38%) of 269 patients. Of the 102 patients with management changes, 76 patients had a decrease and 26 had an increase in treatment intensity. More patients who had a low recurrence score had a decrease in intensity of management, and more patients with a high recurrence score had an increase in intensity.

Cartwright et al (2014) and Srivastava et al (2014) have also published studies showing the effect of Oncotype DX results on treatment recommendations made using traditional risk classifiers in patients with stage II colon cancer. Cartwright et al (2014) performed a retrospective study predicting that test results may lead to reductions in treatment intensity in a percentage of patients. Srivastava et al (2014) performed a prospective study that directly demonstrated reductions in treatment intensity in a percentage of patients.

This type of study does not determine whether patient outcomes are improved as a consequence of the changes in management, and there are no well-defined treatment protocols that differ according to the risk of recurrence within stage II or within stage III colon cancer.

**Section Summary: Clinical Utility**

Some studies have reported management changes following GEP testing. However, these studies do not report clinical outcomes, and there is no direct evidence to determine whether GEP testing improves health outcomes. A chain of evidence might be constructed if there was evidence that changes in management for patients with stage II colon cancer improved health outcomes. The intensity of surveillance and management may be impacted by results of GEP testing, but the evidence to demonstrate that a change in management improved health outcomes is weak and not definitive. Therefore, the evidence does not demonstrate clinical utility.
SUMMARY OF EVIDENCE

For individuals who have stage II or III colon cancer who receive GEP testing, the evidence includes development and validation studies and decision-impact studies. Relevant outcomes are disease-specific survival, test accuracy and validity, and change in disease status. The available evidence has shown that GEP testing for colon cancer can improve risk prediction, particularly the risk of recurrence in patients with stage II or III colon cancer. However, the degree of difference in risk conferred by the test is small. Evidence to date is insufficient to permit conclusions on whether GEP classification is sufficient to modify treatment decisions in stage II or III patients. Studies showing management changes as a consequence of testing do not demonstrate whether such changes improve outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

References


Policy History
Original Effective Date: 04/13/2010
Current Effective Date: 03/21/2018
04/08/2010 Medical Policy Committee approval
04/21/2010 Medical Policy Implementation Committee approval. New policy.
04/07/2011 Medical Policy Committee approval
04/13/2011 Medical Policy Implementation Committee approval. No change to coverage.
04/12/2012 Medical Policy Committee review
04/25/2012 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/04/2013 Coding revised.
Multigene Expression Assays for Predicting Recurrence in Colon Cancer

Policy # 00257
Original Effective Date: 04/13/2010
Current Effective Date: 03/21/2018

04/04/2013 Medical Policy Committee review
04/24/2013 Medical Policy Implementation Committee approval. Changed investigational statement to include all gene expression assays, instead of only Oncotype Dx.
03/06/2014 Medical Policy Committee review
03/19/2014 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/05/2015 Medical Policy Committee review
03/20/2015 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/03/2015 Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
03/03/2016 Medical Policy Committee review
03/16/2016 Medical Policy Implementation Committee approval. Added stage 3 to existing INV statement.
01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes
03/02/2017 Medical Policy Committee review
03/15/2017 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/01/2018 Medical Policy Committee review
03/21/2018 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

Next Scheduled Review Date: 03/2019

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2017 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>81525, 81599, 84999, 88299</td>
</tr>
<tr>
<td>HCPCS</td>
<td>No codes</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>All related diagnoses</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is investigational will be based on a consideration of the following:

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Multigene Expression Assays for Predicting Recurrence in Colon Cancer

Policy # 00257
Original Effective Date: 04/13/2010
Current Effective Date: 03/21/2018

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
   1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
   2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
   3. Reference to federal regulations.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.